NEOT Profile
Neothetics,
Inc. (NEOT) is a clinical stage specialty pharmaceutical company
focused on developing therapeutics for the aesthetic market. The
company's lead product candidate is LIPO-202, which is designed to
reduce localized fat deposits and contour specific areas of the body.
LIPO-202 is a first-in-class injectable drug that utilizes a
proprietary formulation of salmeterol xinafoate, a long-acting beta-2
adrenergic agonist (LABA), to target adipose tissue. The drug is
designed to induce apoptosis, or programmed cell death, in adipocytes
(fat cells) while leaving other tissue types unaffected. This results
in a reduction in the number and size of adipocytes and an improvement
in the contour of the treated area.
The company is initially
developing LIPO-202 for the reduction of submental (double chin) fat.
The drug has completed a phase II clinical trial, which demonstrated
statistically significant reductions in submental fat volume and
improvements in patient satisfaction compared to placebo. Neothetics
plans to initiate a phase III clinical trial for LIPO-202 in the near
future.
In addition to LIPO-202, Neothetics is developing a
pipeline of product candidates for the aesthetic market, including
drugs for the treatment of cellulite and the improvement of skin
laxity.
Neothetics was founded in 7/15/2009 and is
headquartered in San Diego, California. The company went public in
November 2014 and trades on the NASDAQ under the ticker s
|
